BioPharmSignal logoBioPharmSignal

Biotech News

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

Exagen (XGN)ExagenEarnings

CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market opens on Monday, May 11, 2026. John Aballi, President and Chief Executive

Related news

XGNExagen2026-07-21 13:00 EST

Exagen to Announce Second Quarter Financial Results on August 4, 2026

XGNExagen2026-08-04 12:00 EST

Exagen Inc. Reports Second Quarter 2026 Financial Results

OSUROraSure Technologies, Inc.2026-07-22 20:10 EST

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th

IMVTImmunovant2026-07-23 20:05 EST

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

HCWBHCW Biologics2026-05-14 20:25 EST

HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

ANABAnaptysBio, Inc.2026-05-12 20:15 EST

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

AVTXAvalo Therapeutics2026-08-06 11:00 EST

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

IMVTImmunovant2026-08-06 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

OSUROraSure Technologies, Inc.2026-08-05 20:05 EST

OraSure Announces Second Quarter 2026 Financial Results

View all latest news

Exagen

Autoimmune Diagnostics Exagen provides diagnostic testing for autoimmune and rheumatic diseases. Its tests are designed to help clinicians resolve diagnostically complex cases and support ongoing disease management. AVISE CTD AVISE CTD is the company's flagship testing service for lupus and other connective-tissue diseases. It combines...

Recent company news

XGNExagen2026-08-04 12:00 EST

Exagen Inc. Reports Second Quarter 2026 Financial Results

XGNExagen2026-07-28 13:00 EST

Exagen Inc. to Participate in Upcoming Investor Conference

XGNExagen2026-07-21 13:00 EST

Exagen to Announce Second Quarter Financial Results on August 4, 2026

XGNExagen2026-06-01 13:00 EST

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

XGNExagen2026-05-11 12:00 EST

Exagen Inc. Reports First Quarter 2026 Results

Stock data

Close
6.59 USD
Market cap
116.45M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States